Amicus Therapeutics

FOLD · NASDAQ

Price unavailable right now.

No price history for this range.

FOLD analyst rating

HoldConsensus of 7 analysts over the last 12 months. 14% rate it a buy.

Strong buy0
Buy1
Hold6
Underperform0
Sell0

12-month price target · 9 analysts

Average $15.81

Low: $14.14
High: $23.10

Upgrades and downgrades

The latest rating actions, newest first

FOLD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Jan 22, 2026	Downgrade	Buy → Hold	$16.00 → $14.50	25%
Leerink Partners	Dec 29, 2025	Downgrade	Outperform → Market Perform	$17.00 → $14.50	34%
Citigroup	Dec 22, 2025	Downgrade	Buy → Neutral	$17.00 → $14.50	36%
Needham	Dec 19, 2025	Downgrade	Buy → Hold	—	38%
Cantor Fitzgerald	Dec 19, 2025	Downgrade	Overweight → Neutral	$21.00 → $14.50	41%
Citigroup	Dec 17, 2025	Initiates	Buy	$17.00	36%
JP Morgan	Nov 6, 2025	Maintains	Overweight	$18.00 → $19.00	48%
Goldman Sachs	Nov 5, 2025	Maintains	Neutral	$9.00 → $11.00	47%

The case for and against

Updated Feb 9, 2026

Bull case

Amicus Therapeutics Inc. has demonstrated robust growth, with Galafold sales experiencing double-digit year-over-year increases, an indicator of sustained demand and market confidence. The company anticipates further expansion in the addressable Fabry market due to advancements in diagnostic testing supported by AI and machine learning, which could enhance patient identification and treatment access. Additionally, promising results for both Atacicept in IgA nephropathy and sparsentan's efficacy in reducing proteinuria reinforce the company's strong position in developing innovative therapies for rare diseases, contributing to a positive long-term outlook.

Bear case

Amicus Therapeutics's stock exhibits a negative outlook primarily due to the disappointing clinical trial results for its product sparsentan, which failed to meet its primary endpoint of change in eGFR slope at week 108 in the DUPLEX trial. Additionally, despite the sizable total addressable market (TAM) of approximately 40,000 FSGS patients in the U.S., concerns arise about the limited therapeutic benefit of sparsentan for patients with high MCP-1 levels, which are linked to worsening kidney function and proteinuria. The combination of these factors has led to a reevaluation of the company's stock status, resulting in a downgrade to Hold.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.